| Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 A Glasgow, J Glasgow, D Limonta, P Solomon, I Lui, Y Zhang, MA Nix, ... Proceedings of the National Academy of Sciences 117 (45), 28046-28055, 2020 | 241 | 2020 |
| The thermostability and specificity of ancient proteins LC Wheeler, SA Lim, S Marqusee, MJ Harms Current opinion in structural biology 38, 37-43, 2016 | 140 | 2016 |
| Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection SK Elledge, XX Zhou, JR Byrnes, AJ Martinko, I Lui, K Pance, SA Lim, ... Nature biotechnology 39 (8), 928-935, 2021 | 139 | 2021 |
| Illumination of growth, division and secretion by metabolic labeling of the bacterial cell surface MS Siegrist, BM Swarts, DM Fox, SA Lim, CR Bertozzi FEMS microbiology reviews 39 (2), 184-202, 2015 | 131 | 2015 |
| Visualizing Attack of Escherichia coli by the Antimicrobial Peptide Human Defensin 5 HR Chileveru, SA Lim, P Chairatana, AJ Wommack, IL Chiang, EM Nolan Biochemistry 54 (9), 1767-1777, 2015 | 107 | 2015 |
| Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 CJ Bracken, SA Lim, P Solomon, NJ Rettko, DP Nguyen, BS Zha, ... Nature chemical biology 17 (1), 113-121, 2021 | 95 | 2021 |
| Engineering interferons and interleukins for cancer immunotherapy PG Holder, SA Lim, CS Huang, P Sharma, YS Dagdas, B Bulutoglu, ... Advanced drug delivery reviews 182, 114112, 2022 | 75 | 2022 |
| Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptor-binding domain compete for ACE2 binding JR Byrnes, XX Zhou, I Lui, SK Elledge, JE Glasgow, SA Lim, ... MSphere 5 (5), 10.1128/msphere. 00802-20, 2020 | 68* | 2020 |
| BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2 AJ Samelson, QD Tran, R Robinot, L Carrau, VV Rezelj, AM Kain, M Chen, ... Nature cell biology 24 (1), 24-34, 2022 | 67* | 2022 |
| Evolutionary trend toward kinetic stability in the folding trajectory of RNases H SA Lim, KM Hart, MJ Harms, S Marqusee Proceedings of the National Academy of Sciences 113 (46), 13045-13050, 2016 | 41 | 2016 |
| Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity I Lui, XX Zhou, SA Lim, SK Elledge, P Solomon, NJ Rettko, BS Zha, ... BioRxiv, 2020.05. 21.109157, 2020 | 37 | 2020 |
| Theranostic targeting of CUB domain containing protein 1 (CDCP1) in pancreatic cancer A Moroz, YH Wang, JM Sharib, J Wei, N Zhao, Y Huang, Z Chen, ... Clinical Cancer Research 26 (14), 3608-3615, 2020 | 29 | 2020 |
| Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2 SA Lim, JA Gramespacher, K Pance, NJ Rettko, P Solomon, J Jin, I Lui, ... MAbs 13 (1), 1893426, 2021 | 28 | 2021 |
| Tracing a protein’s folding pathway over evolutionary time using ancestral sequence reconstruction and hydrogen exchange SA Lim, ER Bolin, S Marqusee Elife 7, e38369, 2018 | 26 | 2018 |
| Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers SA Lim, J Zhou, AJ Martinko, YH Wang, EV Filippova, V Steri, D Wang, ... The Journal of clinical investigation 132 (4), 2022 | 20 | 2022 |
| CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease N Zhao, S Chopra, K Trepka, YH Wang, S Sakhamuri, N Hooshdaran, ... Clinical Cancer Research 28 (14), 3066-3075, 2022 | 11 | 2022 |
| Serial non-invasive monitoring of renal disease following immune-mediated injury using near-infrared optical imaging Y Du, S An, L Liu, L Li, XJ Zhou, RP Mason, C Mohan Public Library of Science 7 (9), e43941, 2012 | 11 | 2012 |
| Split enzymes: Design principles and strategy SA Lim, JA Wells Methods in Enzymology 644, 275-296, 2020 | 10 | 2020 |
| The burst‐phase folding intermediate of ribonuclease H changes conformation over evolutionary history SA Lim, S Marqusee Biopolymers 109 (8), e23086, 2018 | 10 | 2018 |
| Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptor-binding domain compete for ACE2 binding. mSphere 2020. 5 (5) JR Byrnes, XX Zhou, I Lui, SK Elledge, JE Glasgow, SA Lim, ... | 5 | |
